Novo Nordisk to Discontinue Multiple rDNA Insulin Products in India
The CDSCO's expert panel consented for firm's proposal for discontinuation of products noting that alternative therapies are available in Indian market.;
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has given its consent to Novo Nordisk (India) Private Limited for the discontinuation of multiple Insulin (recombinant DNA origin) drug products from the Indian market.
The discontinuation, as noted, is a business decision and does not affect the safety or efficacy of insulin therapies currently available in India, as the committee has confirmed the availability of alternative therapies.
The matter was discussed at the SEC meeting held on August 20, 2025, at CDSCO headquarters in New Delhi. Novo Nordisk presented its proposal to discontinue several of its Insulin drug products manufactured using recombinant DNA technology.
The committee noted that, "the firm has proposed for the discontinuation of products based on a business decision and not due to any safety or efficacy concerns and further noted that alternative therapies are available in Indian market.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.